Skip to main content
. 2021 Jun 24;107(5):1086–1094. doi: 10.3324/haematol.2021.278438

Figure 1.

Figure 1.

Progression-free survival in patients aged ≥60 years. (A) Modified progression-free survival (PFS) per independent review facility after a median follow-up of 25 months. (B) PFS per investigator after a median follow-up of 60.9 months. A+AVD: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; CI: confidence interval; HR: hazard ratio; INV: investigator; IRF: independent review facility.